Put companies on watchlist
AEVIS VICTORIA SA
ISIN: CH0478634105
WKN: A2PLW7
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

AEVIS VICTORIA SA · ISIN: CH0478634105 · EQS - adhoc news (69 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1427561
24 August 2022 03:46PM

CHF 409.8 million) in the first semester of 2022


AEVIS VICTORIA SA / Key word(s): Sales Result
AEVIS VICTORIA SA – AEVS.SW: Revenues up by 42.6% to CHF 584.2 million (2021: CHF 409.8 million) in the first semester of 2022

24-Aug-2022 / 15:46 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 24 August 2022

AEVIS VICTORIA SA – AEVS.SW: Revenues up by 42.6% to CHF 584.2 million (2021: CHF 409.8 million) in the first semester of 2022

The various acquisitions in the hotel and hospital segments are bearing fruit. Organic growth amounts to 9.8%.

Consolidated revenues of AEVIS VICTORIA increased considerably in the first half of 2022, due to the normalization of the situation in the hotel sector and the various acquisitions completed in 2020, 2021 and 2022. Total revenues increased by 42.6% to CHF 584.2 million (2021: CHF 409.8 million), driven by organic growth of 9.8% and the consolidation of the recently acquired entities in the hospital sector.

The hotel segment (Victoria Jungfrau) business normalized after the lifting of the Covid-related restrictions and revenues of CHF 80.2 million (2021: CHF 52.9 million) resulted in the first half of 2022. The growth of the segment was mainly organic, as L’Oscar Hotel London, acquired in March 2022, only contributed CHF 1.7 million to revenues. The slow recovery in MICE activities (meetings, incentives, conventions, events) was more than offset by a strong increase in individual guests.

The hospital segment (Swiss Medical Network) achieved gross revenues of CHF 450.0 million (2021: CHF 344.7 million), up by 30.5% due to organic growth of 4.7% and the consolidation of Hôpital du Jura bernois, Klinik Pyramid am See, Rosenklinik and Xundheitzentren. Net revenues (medical fees excluded) increased by 33.9% to CHF 392.2 million (2021: CHF 293.0 million)

AEVIS VICTORIA's investment activities contributed CHF 51.3 million to total revenues, in particular through the sale of the participation in Medgate to Otto Group.

AEVIS VICTORIA will publish its full Half Year Report 2022 on 16 September 2022.

For further information:

AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA - Investing for a better life

AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), the only Swiss private network of hospitals present in the country's three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.



End of Inside Information

1427561  24-Aug-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1427561&application_name=news&site_id=boersengefluester
Visual performance / price development - AEVIS VICTORIA SA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.